<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5572">
  <stage>Registered</stage>
  <submitdate>13/12/2010</submitdate>
  <approvaldate>13/12/2010</approvaldate>
  <nctid>NCT01260350</nctid>
  <trial_identification>
    <studytitle>Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3</studytitle>
    <scientifictitle>A Multi-center, Open-Labeled Exploratory Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 400 mg and Ribavirin for 12 Weeks With and Without Pegylated Interferon in Treatment-Naïve Patients With Chronic HCV Infection Genotype 2 or Genotype 3</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Medsafe</secondaryid>
    <secondaryid>P7977-0523</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SOF
Treatment: drugs - RBV
Treatment: drugs - PEG
Treatment: drugs - LDV
Treatment: drugs - GS-9669
Treatment: drugs - LDV/SOF

Experimental: Group 1: SOF+RBV 12 wk: GT 2 or 3, TN - Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.

Experimental: Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.

Experimental: Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.

Experimental: Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.

Experimental: Group 5: SOF 12 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.

Experimental: Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.

Experimental: Group 7: SOF+RBV 12 wk: GT 1, TE - Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.

Experimental: Group 8: SOF+RBV 12 wk: GT 1, TN - Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.

Experimental: Group 9: SOF+RBV 12 wk: GT 2 or 3, TE - Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.

Experimental: Group 10: SOF+RBV 8 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.

Experimental: Group 11: SOF+RBV 12 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.

Experimental: Group 12: SOF+RBV+LDV 12 wk: GT 1, TE - Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.

Experimental: Group 13: SOF+RBV+LDV 12 wk: GT 1, TN - Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.

Experimental: Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE - Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.

Experimental: Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN - Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.

Experimental: Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis - Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.

Experimental: Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis - Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.

Experimental: Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN - Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.

Experimental: Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE - Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.

Experimental: Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac - Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.

Experimental: Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN - Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.

Experimental: Group 22: LDV/SOF FDC 6 wk: GT 1, TN - Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.


Treatment: drugs: SOF
Sofosbuvir (SOF) tablets administered orally once daily

Treatment: drugs: RBV
Ribavirin (RBV) capsules administered orally in a divided daily dose

Treatment: drugs: PEG
Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly

Treatment: drugs: LDV
Ledipasvir (LDV) tablets administered orally once daily

Treatment: drugs: GS-9669
GS-9669 tablets administered orally once daily

Treatment: drugs: LDV/SOF
LDV/SOF fixed-dose combination (FDC) tablet administered once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Experienced Adverse Events - Adverse events (AEs) occurring from baseline (Day 1 for all groups) to 30 days following the last dose of study drug were summarized across the participant population. A participant was counted once if they had a qualifying event.</outcome>
      <timepoint>Up to 12 weeks plus 30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12) - SVR12 was defined as HCV RNA &lt; the limit of detection (LOD; &lt; 15 IU/mL) 12 weeks after the last dose of study drug.</outcome>
      <timepoint>Posttreatment Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HCV RNA &lt; LOD at Week 6</outcome>
      <timepoint>Week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HCV RNA &lt; LOD at Week 8 - Data are not presented for Group 21 which ended treatment after Week 6.</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HCV RNA &lt; LOD at Week 12 - Data are not presented for Groups 6, 10, and 21 which ended treatment after Week 8 or Week 6.</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in HCV RNA at Week 6</outcome>
      <timepoint>Baseline to Week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in HCV RNA at Week 8 - Data are not presented for Group 21 which ended treatment after Week 6.</outcome>
      <timepoint>Baseline to Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in HCV RNA at Week 12 - Data are not presented for Groups 6, 10, and 21 which ended treatment after Week 8 or Week 6. Data are not presented for Groups 16, 17, 18, and 20 because participants with detectable HCV RNA discontinued due to protocol-specified stopping rules.</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Virologic Failure - The percentage of participants with on-treatment virologic failure (viral breakthrough, rebound, or nonresponse) or following treatment (viral relapse) was summarized.
On-treatment virologic failure was defined as:
Viral breakthrough (confirmed HCV RNA = LOD after having previously had HCV RNA &lt; LOD while on treatment),
Viral rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment, or
Nonresponse (HCV RNA persistently = LOD through 6 weeks of treatment)
Viral relapse was defined as confirmed HCV RNA = LOD during the posttreatment period having achieved HCV RNA &lt; LOD at the last on-treatment visit.</outcome>
      <timepoint>Up to Posttreatment Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Chronic Genotype 2 or 3 HCV-infection or Genotype 1, serum HCV RNA = 50,000 IU/mL

          -  Not co-infected with HIV

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of any other clinically significant chronic liver disease

          -  Pregnant or nursing female or male with pregnant female partner

          -  History of significant drug allergy to nucleoside/nucleotide analogs.

          -  Participation in a clinical study within 3 months prior to first dose

          -  Positive result for significant drug use at Screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>292</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to assess the safety and tolerability of sofosbuvir (SOF) 400 mg with and
      without ribavirin (RBV) and/or with and without pegylated interferon alfa-2a (PEG) in
      subjects with genotype 1, 2 or 3 hepatitis C (HCV) infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01260350</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert H. Hyland, DPhil</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>